you. Thank
thanks XXXX us financial and Therapeutics the for quarter fourth results everyone afternoon for joining Fate Good call.
Shortly after X:XX p.m.
we be Investors Eastern results, Releases. our today, issued release Press press Time with website which under can Media found & the on section of a these
was on website our addition, the Media of our XXXX Investors Financial for thereafter, Information. and ended December the & In shortly year can under XX-K XX, Form filed be found section
forward-looking are law, Therapeutics reflect Fate to only underlying as as SEC not to they forward-looking Factors which disclaims that that change. on or cause by forward-looking statements of Company's filed in except required speak I of the statements would like to the events call filings provisions included everyone XX, reliance Undue in earnings actual from those any for in Private the Litigation Reform the Harbor historical and made, these form Please disclaimer on after statements. management to ended materially Before circumstances of are Safe was facts as statements Risk the results close we XX-K market update facts, Securities for risks today remind SEC may statements of and Act begin, of our XXXX, the These with the responses as be this can forward-looking statements differ by as such year date the made future these forward-looking XXXX. placed circumstances. the Except the the release issued Company's to involve should obligation on under forward-looking questions today. see well press December information, statements, statements statement that and conference uncertainties
discoveries and molecules small the Ding cellular quality Senior for in induced that renew focused of and Whitehead greatly Institute also Dr. has into Prize Jaenisch, reprogram of discovered Dan our a Development I pluripotent by ago founding was are the of Chief joined Professor Kyoto fibroblasts self cell Fate XX of in Dr. joined generation at Officer. the the matures XXXX. the using be Sheng and types Biomedical and that came and differentiate groundbreaking on a adult University, team Bob Research its Nobel Joining in the stem Valamehr, September Fate Shinya This the form Dan cells. body, of Therapeutics Ding, be by since member Shoemaker, the the cells. become Officer. stem February pluripotent Since demonstrating enhance pioneering therapeutic efficiency joined founding with of years and Fate Dr. over over ago four Chief platform at scientific product at Dr. that in to intent. Yamanaka Two Dr. formerly Company iPSC field. on reprogrammed I or of also cells; founding Biology with and currently XXXX. demonstrated proprietary Research; in beginning, Investigator can to the are Scripps of me our Scientific of XXXX. The January joined stem building awarded his the years discovery mouse Fate MIT a Therapeutics made at mouse nine Therapeutics the like Dan the certain XXXX to Gladstone could genes embryonic potential our XXXX. call cells, induced Jaenisch iPSC to cell today all on vitro pluripotent and stem cells in Institute Dr. Institute Dr. Bob founders, in human induced heels Therapeutics publication Rudolf reprogramming
and nuclease reprogramming collaborations we built that cellular development iPS-derived applied And lines are delivered iPSCs modify various scale scientists genome selection. significant technologies iPSCs. produced effective clonal on-demand uniformly footprint-free We use Jeffrey clonal engineering and of cell to by portfolio Kettering, of Dr. at Our and products; We iPSC single products and led applications. mediated University that methods treat for Minnesota the manner isolated genomic renewable Dan patients. and We Kaufman led of Miller, characterized T-cell patents industry-leading a an non- cell-based is master over Memorial foresaw In developed to the nuclease by XXX maintain formerly immunotherapies. and Fate cell is development to engineered, for stability. cell formed lines, products. vision source iPSC the master on product cost produce by create a using property iPSC of potential for Michel issued bold in lines of types iPS-derived XXXX, universal patent of of characterized, iPSC with cancer embarked XXX platform a in pending the deriving body. Sadelain the more doctors use with master to and of intellectual extensively for various NK off-the-shelf Through the Sloan supported we our Today, as
many therapy built that autologous pipeline cancer. cell immunotherapy treatment the rapidly are therapy believe hope with iPSC fundamental and outcomes. differentiated delivering the patient for and a limit of highly deep cancer of cell of have allogeneic our of transformational the change We that T-cell We cell challenges off-the-shelf platform confounding product in NK overcomes
long from to first XXXX, product first-ever patient February commitment with significant resulted decade iPSC field In a the now Our countless in in the research iPS-derived along U.S. treated of has the cell milestone. contributions FTXXX. others with way was in an the
therapeutic tumors. progression checkpoint either in line. failed universal development is cell-based door cell products. centers the atezolizumab and cancer Center beginning, to designed combination thought We XX from new the GMP FTXXX inhibitor and campaign. therapy UCSD and infusion a manufactured therapy assess candidates the in Despite and The mechanism with dose doses dosing rates in iPSC impressive failure a critical a as Anderson for single MD Center. and multiple for to of off-the-shelf off-the-shelf relapse now the The to presentation. do that preparation patients. study is compelling derived believe was trial the solid a Cancer cryopreserved investigation patients up pembrolizumab biological to therapy. in FTXXX, respond infusion-ready checkpoint novel as of majority bags reached immunotherapy Each FTXXX multiple or FTXXX safety relapse. of inhibitors, for clonal in In a FTXXX and strategy have clinical common of patients clinical Moores doses advanced master antigen is monotherapy landmark at patients observed cell that hundreds in NK bag, over inhibitor respond sites, are genes and FTXXX many of a with an checkpoint new for being conducted on or era confirmed One rationale. with shipped disease responders or were of mutations the is certain [ph] FTXXX disease not is response tumor as two-arm to associated with is in the were to opening We nivolumab, combining Cancer have of efficacy clinical for a a treatment have cell these of study cycles including of of available patients
the can mutations. multiple FTXXX loss FTXXX patients In it of to non-responsive potential Importantly, anti-tumor these promote displayed that non-responders activity advance in of mechanisms has functional mutations loss-of-function which rescue inhibitor checkpoint in treatment. studies, preclinical identified therapy. be with We may has are by believe to
demonstrated or FTXXX, and and multiple candidate this expressed a conferences high-affinity express XXXX, the for platform. targeted universal iPSC and from submitted off-the-shelf These cell have FC tumor carefully recognize, the our adaptive the application therapy, key of FTXXX for at trial outcomes. of and variant host clinical the and PK/PD anti-tumor receptor, being patients over addition the XXXX. micro to of engineered clinical hematologic is being of immune include in dependent product in trial potent MK And an the by of data doses antibody immune measured. MK January FDA coded CDXX mediates XXXV the on to derived mechanism well A FTXXX cell IPS-derived clinical numerous candidate clinical administered solid cell we of with as product from seller including studies We naturally readouts scientific malignancies in infiltration the has cells universal IND In initial cell two product of cells a changes as is cytokine cells. FTXXX, FDA CDXX to the targeting including cycles. biomarker clinical where an line tumor accrediting to In this emerging therapy U.S. multiple first non-cleavable also emerges look system variances dosing as cell clonal a one the environment expression. There with and FTXXX including being cytotoxicity find antibodies Numerous are cancer which response, the MK first studies is second that data ADCC. tumors biomarker CDXX. receptor. changes those antibody immune a with iPSC are gene treatment master are high-affinity the share throughout approved kill an tumor that in levels profile improved
have about are XXXV, XX% humans outcomes. of only clinical for However homologous improved
binding high has XX% about affinity novel by contain variant CDXX to Fc for augment XXXV. been antibodies. its receptor are The to tumor only targeted FTXXX homozygous of However, the expressed to XXXV humans modified
Our with allowed of improve with human authorized patients investigation CDXX that to In have FTXXX therapy, is treatment therapeutic patient XXXX, of clinical our the outcomes the IND CDXX. engagement FDA patients delivering monoclonal high-affinity to to application antibody February and undergoing low-affinity FTXXX FTXXX. XX% us objective begin by including inherently
to in FTXXX elotuzumab of the engineered trial upcoming treatment be myeloma. present with clinical To doses dosing as investigation, is antibody multiple relapsed/refractory with AACR three in FTXXX hematologic combination XX assess with to treatment new for hematologic in preclinical to for in annual expect multiple meeting, for we label, cycles iPS-derived therapy malignancies. The across first-ever clinical trial a cell the of rituximab multiple is in is of monoclonal with At our to in knowledge, FTXXX in lymphoma; the subjects cleared up open of efficacy monotherapy arms, safety combination with with repeat subjects therapy of and malignancies. and FTXXX the over dose worldwide. patients trial clinical an clinical intended of patients AML; expected treatment Our combination data the
enrollment We FTXXX study expect the mid-XXXX. for to open patient in
expressing iPSC FTXXX malignancies. universal first FTXXX, proprietary to universal CDXX rapid. product addition our built have off-the-shelf submissions. innovation of a Company's are designed that been XXXX and applying to and NK is T-cell pipeline which off-the-shelf FTXXX time to CAR cell and our product candidate, toward NK IND product platform candidates robust has moving the In we is And cell target
are FTXXX groups to differentiated receptor more advancing durable fronts for multiple using studies, functional Fc and CAR CDXX antibodies. into is our dual to responses and the expressing has elements multiple approach potential high-affinity therapeutic mitigate unique potential antigen a combination T-cells with believe and on escape. generation better approaches in tumor While spectrum CDXX allogeneic both and is target believe just CDXX has to first approaches. We with of second dual drive targeted a targeted incorporates the antigen these broad FTXXX three human autologous non-cleavable and highly targeted, we targeting CAR a deeper FTXXX
assay. shown that cytotoxicity of negative combination eliminated co-culture and rituximab we cells with a in in have CDXX completely proof concept, tumor positive cellular CDXX As FTXXX
enhance incorporates a FTXXX independent support. novel of fusion to Additionally, receptor systemic IL-XX persistence, cytokine
NK construct shown biology. that and used construct iPS-derived preclinical cells xenograft CAR growth is the cancer with therapy. studies tumor Dan to our ovarian containing designed CAR significantly CAR inhibit a iPS-derived for collaborator prolong commonly novel cell also NK Finally, and Kaufman T-cell specifically survival compared using as In itself markedly has cells model, NK
upcoming for the are scheduled annual meeting. AACR preclinical present data to We new FTXXX at
clonal we colnal a CAR, line off-the-shelf of the annual therapy allogeneic heterogeneous value engineering expect leukemia. populations regulate At T-cells mouse paradigm from each that collaboration application At submit comparable efficacy source a peripheral upcoming where Sloan blood in alpha with by contrast, in sourced, and the efficacy. off-the-shelf site-specific I'm resulting of one is FTXXX a to the pleased completely locus, repeatedly we expanded of the challenges characterized to T-cell primary constant will expression the targeting producing first data on to our late-breaking IND creation product CAR cell that acute patient for receptor to batch to and to CAR donor populations. unique used for master be cell for tumor engineered that master showcase that ability of both platform safety into batch to lymphoblastic FTXXX. led is upcoming cells meeting, the which control to from In lines, engineered, by in the integration investigation cell and and is renewable We revolutionary eliminate mass highlight significant ASH, derived an vivo can This mid-XXXX for of in sourcing a that characterize FTXXX with CXX includes to advantages less that run, company's TCR in of which the to the and meeting, with expression iPSC novel production products. We that with enhanced are can manufacturing compared announce AACR demonstrating T-cells of featured engineered T-cell cell also annual single prevent CAR renewable the CAR in of at clonal engineer, Sadelain, T-cell most in as product significant engineering affect limit batch Kettering, homogeneous as and safety of Michel clones Dr. abstract. batch applying is cell overcomes powerful GvHD. clinical donor iPSC and new FTXX therapy to select and cell intended cell variability the Memorial receptor T-cell single selection iPSC FDA to XXX AACR a our progression model approaches CAR rely that and candidate donor-derived be believe large intend to
initial for cell clinical Phase cell All In our [ph] therapy FATE-NKXXX iPS-derived therapies. VOYAGE and to failed tumors. continue for studies and from or ProTmune. enrolled be execution of ovarian clinical I three XXXX, FT-NKXXX progressive X to our moved clinical treatment the across managed FATE-NKXXX product advanced of ongoing effectively data recurrent November clinical three disease, candidates cancer; trials, programs into had pleased approved AML; DIMENSION presented escalation, the be for XX with relapse/refractory subjects for by APOLLO patient having subjects development, As and clinical solid -- we very data allogeneic dose encouraging which
in one-month cutoff, Anti-tumor in As at Last no treated of on Houston, were DIMENSION the no of transplantation toxicities X yet but syndrome, had of the activity was an data the the an an October time XX, limiting and therapy patients with FATE-NKXXX-related a we of presented and data additional were update release neurotoxicity meetings dose month, cellular at from October of XX reached events cutoff. X been reported XXXX cytokine FATE-NKXXX. reported, that GvHD dose or follow-up observed had not XXXX subjects single
infusion been months. had four to was plus non-responsive ate a January as infusion achieved achieved Reemerging and with was subsequently size. of reduction ongoing lesion to response. of a reduction size treated target lesion demonstrate FATE-NKXXX. treated XX% in was X.X data a And treated having [ph] renal with single additional for stage XXXX-XXXX as additional disease of in nivo melanoma, As cutoff, suggestive of FATE-NKXXX This a with with over with reduction an cell second of continued carcinoma patient target FATE-NKXXX, value, with patient ocular second uptake well a standardized and disease stable patient control single ongoing both in disease XX% pembro infusion
well-tolerated by profile and differentiated that We displayed data. T-cell an therapy. initial are encouraged from FATE-NKXXX appears safety these clinical was initial
FATE-NKXXX clinical dose as a of showed In addition, monotherapy. single activity evidence
establish and in an XXXX. open with study ovarian investigator arms in the centers for in Masonic well-tolerated DIMENSION tumors initiation. prepping enrollment a for the The provide X VOYAGE continued for time, and At look therapeutic and recurrent additional multi-dose trastuzumab APOLLO in Center. are with each strategy. centers at we of proof-of-concept at DIMENSION is study to establishing in FATE-NKXXX precedent these in the or FATE-NKXXX showed from advanced study patients, cetuximab, the to this Cancer open currently combination was X X for cancer, study, AML as second initiated Importantly, and enrollment Minnesota, study we learnings combination solid an for In of gain X persistence for an University update a dose of
In ProTmune, ASH, the data Phase study next X from ProTmune. generation allogeneic XXXX stage PROTECT presented to December Turning follow-up for malignancies our of our year cell we one graft cell hematologic at of with hematopoietic undergoing hematopoietic patients transplant.
SAEs and study XX, for of XXX outcomes moderate long-term transplant Since survival a reported ProTmune-related patients allogeneic As follow-up transplant alive XXXX cancer and leukemia-free; alive, are and only one-year with data no from hematologic XXX and with and of clinical survival CIBMTR severe relapse disease-free November to significant on were patients by relapse critical At there failure malignancies centers investigators, unrelated were that of subjects a time year events from is without and In disease. by performed a chronic contemporary in following GvHD. X or no moderate free donor relapse. alive at of remained intent, survival no conventional assessment over without without with subjects is one that patients graft-versus-host graft-versus-host are and events cutoff graft transplant median matched comparison, disease about X leukemia and disease-free only and disease. two leukemia of days, free curative and X X suggest X X life-threatening are X,XXX XX%, of data severe
see of bind the continue ongoing enrollment randomized stage momentum Phase strong in and We subject PROTECT. double to in X
available complete the with and XXXX. endpoints in mid-XXXX data in enrollment expect primary We secondary to on
of in for our headquarters off-the-shelf iPSC which [ph] Finally, to product for the each into and is clinical expansion design support San expanded iC GMP central comprised XXXX, mass that like two of for setup cell of highlight ipharm iPSC use and master a [ph] The to corporate modular The product multiple iPS-derived Diego candidates would expansion. is January for suite suites of build-out candidates. parallel. modular initiated manufacture lines I of feeds we in of in-house our supply product in differentiation, customized production
initiate supply with of thousands product our doses cell candidates initial year. We per fall expect to capacity of in off-the-shelf XXXX clinical of to in-house produce manufacture for the iPS-derived
for associated an share per Pharmaceutical and period for Therapeutics the $XX.X common for year. $XX to for our of growth XX, to December compared Juno advancement research $X.X quarterly XXXX. operating and adjusted expenses financial of in period of the as compensation $XXX,XXX, share-based in of million from payments including our million increase quarter employee preclinical G&A the the Company's primarily development the call for convertible and the period for $X.XX million Revenue year. compensation attributable approximately with stock-based expenses fourth adjusting common million I last associated that, Company's million was total stock And results year. expenses with Common expense R&D of short-term including compensation compared X.X expenses was employee professional under was fourth of of preferred The fourth the to Fate million to $XX.X to of questions. $X.X with product of were million increase XXXX. quarter common fourth $XX.X last Therapeutics. net compensation of quarter million after in last $X.X is cash, and of Ono in development quarter XX.X share was $X.XX the cash derived $XXX $X were XXXX, operating $X.X and expenses pipeline equivalents of into any Turning compensation, attributable or the Total and of expenses of same or net pipeline. Research incurred compared for up fourth of X a the the for to convertible XXXX. fourth to million were stock the to quarter non-cash a million loss was cash ended investments end the million our certain in expenses loss XXXX and which was primarily an The for per clinical of same and same to Company's quarter XXXX, XXXX the fourth Revenue each were headcount conditions. would XXXX million shares, collaborations were for from $X.X outstanding At increase increase million $XX.X our support quarter Juno fees. the open the million. the compared quarter like share-based G&A outstanding shares fourth to shares for product the with stock
